Jonathan T. Lei,Jieya Shao,Jin Zhang,Michael Iglesia,Doug W. Chan,Jin Cao,Meenakshi Anurag,Purba Singh,Xiaping He,Yoshimasa Kosaka,Ryoichi Matsunuma,Robert Crowder,Jeremy Hoog,Chanpheng Phommaly,Rodrigo Goncalves,Susana Romalho,Raquel M. Peres,Nindo Punturi,Cheryl Schmidt,Alex Bartram,Eric Jou,W V. Lai,Oliver Hampton,Anna Rogers,Ethan Tobias,Poojan Parikh,Sherri R. Davies,Shunqiang Li,Cynthia X. Ma,Vera Suman,Kelly K. Hunt,Mark A. Watson,Katherine A. Hoadley,E A. Thompson,Xi Chen,Shyam M. Kavuri,Chad J. Creighton,Christopher A. Maher,Charles M. Perou,Svasti Haricharan,Matthew J. Ellis

Abstract:Abstract RNA sequencing detects estrogen receptor alpha gene (ESR1) fusion transcripts in estrogen receptor positive (ER+) breast cancer but their role in disease pathogenesis remains unclear. Herein we examined multiple in-frame and out-of-frame ESR1 fusions and found only two, both identified in advanced endocrine treatment resistant disease, encoded stable and functional in-frame fusion proteins. In both examples, ESR1-e6>YAP1 and ESR1-e6>PCDH11X, the N-terminal, DNA binding and dimerization motifs encoded by exons 2-6 were fused to C-terminal sequences from the partner gene. Functional properties included estrogen-independent growth, constitutive expression of ER target genes, anti-estrogen resistance, induction of cellular motility in vitro and the development of lung metastasis in vivo. Chromatin immunoprecipitation and RNA sequencing experiments showed both fusions uniquely activated a metastasis-associated transcriptional program. ESR1-e6>YAP1 and ESR1-e6>PCDH11X-induced growth remained sensitive to a CDK4/6 inhibitor, palbociclib, and a patient-derived xenograft (PDX) expressing the ESR1-e6>YAP1 fusion was also responsive. Transcriptionally active ESR1 fusions therefore trigger both endocrine therapy resistance and metastatic progression explaining the association with fatal disease progression, although CDK4/6 inhibitor treatment is predicted to be effective. Citation Format: Jonathan T. Lei, Jieya Shao, Jin Zhang, Michael Iglesia, Doug W. Chan, Jin Cao, Meenakshi Anurag, Purba Singh, Xiaping He, Yoshimasa Kosaka, Ryoichi Matsunuma, Robert Crowder, Jeremy Hoog, Chanpheng Phommaly, Rodrigo Goncalves, Susana Romalho, Raquel M. Peres, Nindo Punturi, Cheryl Schmidt, Alex Bartram, Eric Jou, W V. Lai, Oliver Hampton, Anna Rogers, Ethan Tobias, Poojan Parikh, Sherri R. Davies, Shunqiang Li, Cynthia X. Ma, Vera Suman, Kelly K. Hunt, Mark A. Watson, Katherine A. Hoadley, E A. Thompson, Xi Chen, Shyam M. Kavuri, Chad J. Creighton, Christopher A. Maher, Charles M. Perou, Svasti Haricharan, Matthew J. Ellis. Functional and therapeutic significance of ESR1 gene fusions in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5240.

Editor's Note: 4E-Binding Protein 1, a Cell Signaling Hallmark in Breast Cancer That Correlates with Pathologic Grade and Prognosis

Editor's Note: Eph-B2/Ephrin-B2 Interaction Plays a Major Role in the Adhesion and Proliferation of Waldenstrom's Macroglobulinemia

Abstract 5240: Functional and Therapeutic Significance of ESR1 Gene Fusions in Breast Cancer

[Expression and Clinical Significance of Ser10 Phosphorylated P27(kip1) Protein in Human Breast Carcinoma].

Editor's Note: Both TEAD-Binding and WW Domains Are Required for the Growth Stimulation and Oncogenic Transformation Activity of Yes-Associated Protein

Editor's Note: Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment

Editor's Note: Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma

Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer

Eif4e Binding Protein 1 Expression is Associated with Clinical Survival Outcomes in Colorectal Cancer

Editor's Note: Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma

Withdrawal: A Novel Human Phosphatidylethanolamine-Binding Protein Resists Tumor Necrosis Factor Α-Induced Apoptosis by Inhibiting Mitogen-Activated Protein Kinase Pathway Activation and Phosphatidylethanolamine Externalization.

Editor's Note: Detection of Wilms' Tumor Antigen–Specific CTL in Tumor-Draining Lymph Nodes of Patients with Early Breast Cancer

Editor's Note: Cyclin-Dependent Kinase 5 Decreases in Gastric Cancer and its Nuclear Accumulation Suppresses Gastric Tumorigenesis

Editor's Note: Tumor Escape from Endogenous, Extracellular Matrix–Associated Angiogenesis Inhibitors by Up-Regulation of Multiple Proangiogenic Factors

EXPRESSION OF CONCERN: A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells

Activated growth signaling pathway expression in Ewing sarcoma and clinical outcome

EBP50 Exerts Tumor Suppressor Activity by Promoting Cell Apoptosis and Retarding Extracellular Signal-Regulated Kinase Activity

Editor's Note: Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia

Expression of Concern to IRE1a constitutes a negative feedback loop with BMP2 and acts as a novel mediator in modulating osteogenic differentiation

Expression of cytoskeletal binding protein 4. 1N in Ewing's sarcoma and its clinical significance

CD70 is a Potential Target Biomarker in Peripheral T‐cell Lymphomas